Melodiol Global Health (ASX:ME1) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ME1 Overzicht aandelen

Melodiol Global Health Limited houdt zich bezig met de ontwikkeling, kweek en distributie van recreatieve en medicinale cannabisproducten in Europa, Canada, Australië en Azië.

Over het bedrijf

ME1 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Risicoanalyse

De winst is de afgelopen 5 jaar met 17.7% per jaar gedaald

Negatief eigen vermogen

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( A$1M )

+ 1 meer risico

Melodiol Global Health Limited Concurrenten

Wellfully

ASX:WFL

AU$1.5m

Invex Therapeutics

ASX:IXC

AU$6.1m

Firebrick Pharma

ASX:FRE

AU$11.5m

Acrux

ASX:ACR

AU$15.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Melodiol Global Health
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.001
52 Week Hoogtepunt	AU$4.20
52 Week Laag	AU$0.001
Bèta	2.5
11 maand verandering	0%
3 maanden verandering	-50.00%
1 Jaar Verandering	-99.97%
33 jaar verandering	-100.00%
5 jaar verandering	-100.00%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

May 01

Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding

Mar 02

Recent updates

Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

May 01

Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding

Mar 02

Here's Why Creso Pharma (ASX:CPH) Can Afford Some Debt

May 11

Rendement voor aandeelhouders

	ME1	AU Pharmaceuticals	AU Markt
7D	0%	-6.3%	-0.7%
1Y	-100.0%	82.1%	17.1%

Rendement versus industrie: ME1 presteerde slechter dan de Australian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 98.5 % opleverde.

Rendement versus markt: ME1 presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 17.9 % opleverde.

Prijsvolatiliteit

Is ME1's price volatile compared to industry and market?
ME1 volatility
ME1 Average Weekly Movement	43.5%
Pharmaceuticals Industry Average Movement	10.6%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.7%

Stabiele aandelenkoers: De aandelenkoers van ME1 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ME1 is het afgelopen jaar gedaald van 63% naar 44%, maar is nog steeds hoger dan 75% van de Australian -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	n/a	Will Lay	melodiolglobalhealth.com

Melodiol Global Health Limited houdt zich bezig met de ontwikkeling, teelt en distributie van recreatieve en medische cannabisproducten in Europa, Canada, Australië en Azië. Het bedrijf is betrokken bij de ontwikkeling en commercialisering van nutraceutische producten en medische benodigdheden. Het bedrijf was voorheen bekend als Creso Pharma Limited en veranderde zijn naam in Melodiol Global Health Limited in juni 2023.

Melodiol Global Health Limited Samenvatting

Hoe verhouden de winst en inkomsten van Melodiol Global Health zich tot de beurswaarde?
ME1 fundamentele statistieken
Marktkapitalisatie	AU$1.13m
Inkomsten(TTM)	-AU$35.52m
Inkomsten(TTM)	AU$18.92m

0.1x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is ME1 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ME1 resultatenrekening (TTM)
Inkomsten	AU$18.92m
Kosten van inkomsten	AU$18.10m
Brutowinst	AU$817.00k
Overige uitgaven	AU$36.34m
Inkomsten	-AU$35.52m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.032
Brutomarge	4.32%
Nettowinstmarge	-187.73%
Schuld/Eigen Vermogen Verhouding	-232.0%

Hoe presteerde ME1 op de lange termijn?

Bekijk historische prestaties en vergelijking

ME1 Overzicht aandelen

Beloningen

Risicoanalyse

Melodiol Global Health Limited Concurrenten

ASX:WFL

AU$1.5m

ASX:IXC

AU$6.1m

ASX:FRE

AU$11.5m

ASX:ACR

AU$15.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding

New major risk - Negative shareholders equity

Recent updates

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding

New major risk - Negative shareholders equity

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited Option Expiring 13 November 2028 Deferred Settlement Deleted from OTC Equity

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215 million.

Melodiol Global Health Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.231808 million.

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 1.022261 million.

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 1.022261 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 1.010906 million.

First half 2023 earnings released: AU$0.013 loss per share (vs AU$0.006 loss in 1H 2022)

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.574725 million.

Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.

Here's Why Creso Pharma (ASX:CPH) Can Afford Some Debt

Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.027 loss in FY 2021)

Creso Pharma Limited (ASX:CPH) entered into a binding letter of intent to acquire Abby & Finn, LLC for $2.5 million.

Creso Pharma Limited Announces Board Changes

Less than half of directors are independent

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

First half 2022 earnings released: AU$0.006 loss per share (vs AU$0.018 loss in 1H 2021)

Sierra Sage Secures USD 214,000 Purchase Order from Walmart

Creso Pharma Limited (ASX:CPH) signed a non-binding, non-exclusive heads of agreement to acquire Dr Pickles Pty Ltd.

Less than half of directors are independent

Creso Pharma Limited, Annual General Meeting, May 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Creso Pharma Limited announced that it expects to receive AUD 5 million in funding

Creso Pharma to Develop New Hemp-Based Lozenge Product

Creso Pharma Limited Launches New E-Commerce Channels

First half 2021 earnings released: AU$0.018 loss per share (vs AU$0.08 loss in 1H 2020)

Creso Pharma Limited (ASX:CPH) completed the acquisition of Halucenex Life Sciences Inc.

Co-Founder & Non-Executive Chairman recently sold AU$4.5m worth of stock

Creso Pharma Limited Launches New Product

Creso Pharma Limited (ASX:CPH) entered into an agreement to acquire Halucenex Life Sciences Inc. CAD 10 million.

Creso Pharma Limited Signs Non-Binding Letter of Intent with ImpACTIVE Holdings Ltd

Full year 2020 earnings released: AU$0.083 loss per share (vs AU$0.10 loss in FY 2019)

Creso Pharma Limited Executes A Non-Binding Letter of Intent with Ceres Natural Remedies

Creso Pharma Limited Revises Earnings Guidance for the Fiscal Year 2021

Creso Pharma Limited Announces Distribution Agreement with Route2 Pharm Pvt Ltd

CBD Oil legal in Australia - Creso Pharma Limited to benefit

Creso Pharma Limited has announced a Derivatives Offering in the amount of AUD 9.523042 million.

Creso Pharma Limited Secures New Purchase Order for its Leading Range of Animal Health Products Anibidiol

Creso Pharma Limited Secures First Purchase Order for Animal Health Products in LATAM

Creso Pharma Limited Announces TGA Decision to Reschedule CBD

New 90-day high: AU$0.23

Creso Pharma Limited Receives New Purchase Orders for Anibidiol® Products

Creso Pharma Limited Receives Second Purchase Order from Pharma Dynamics, South Africa

Creso Pharma Limited announced that it expects to receive AUD 8.992531 million in funding

First half earnings released

Creso Pharma Limited Announces CEO, Miri Halperin Wernli to Take Role of Technology, Innovation and Distribution Head

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Melodiol Global Health Limited Samenvatting

0.1x